CGEM Long Call Strategy
CGEM (Cullinan Therapeutics, Inc.), in the Healthcare sector, (Medical - Pharmaceuticals industry), listed on NASDAQ.
Cullinan Therapeutics, Inc. operates as a biopharmaceutical firm actively advancing its therapeutic candidates through clinical trials. This company is focused on developing innovative treatments primarily for cancer, including those that leverage the immune system (immuno-oncology). Its current roster of investigational drugs comprises CLN-978, CLN-619, Zipalertinib CLN-081/TAS6417, CLN-049, and CLN-617. Patrick A. Baeuerle founded the organization on September 15, 2016, and it is presently headquartered in Cambridge, Massachusetts.
CGEM (Cullinan Therapeutics, Inc.) trades in the Healthcare sector, specifically Medical - Pharmaceuticals, with a market capitalization of approximately $1.13B, a beta of 0.01 versus the broader market, a 52-week range of 5.68-19.43, average daily share volume of 1.1M, a public-listing history dating back to 2021, approximately 111 full-time employees. These structural characteristics shape how CGEM stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 0.01 indicates CGEM has historically moved less than the broader market, dampening realized volatility and producing tighter expected-move bands per unit of dollar exposure.
What is a long call on CGEM?
A long call buys upside exposure with a fixed maximum loss equal to the premium paid; profit accrues if the underlying closes above the strike plus premium at expiration.
Current CGEM snapshot
As of June 29, 2026, spot at $18.34, ATM IV 117.60%, IV rank 19.40%, expected move 33.71%. The long call on CGEM below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 18-day expiry.
Why this long call structure on CGEM specifically: CGEM IV at 117.60% is on the cheap side of its 1-year range, which favors premium-buying structures like a CGEM long call, with a market-implied 1-standard-deviation move of approximately 33.71% (roughly $6.18 on the underlying). The 18-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated CGEM expiries trade a higher absolute premium for lower per-day decay. Position sizing on CGEM should anchor to the underlying notional of $18.34 per share and to the trader's directional view on CGEM stock.
CGEM long call setup
The CGEM long call below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With CGEM near $18.34, the first option leg uses a $18.00 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed CGEM chain at a 18-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 CGEM shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Call | $18.00 | $1.68 |
CGEM long call risk and reward
- Net Premium / Debit
- -$167.50
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- -$167.50
- Breakeven(s)
- $19.68
- Risk / Reward Ratio
- Unbounded
Max profit is unbounded; max loss equals the premium paid times 100. Breakeven is strike plus premium.
CGEM long call payoff curve
Modeled P&L at expiration across a range of underlying prices for the long call on CGEM. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
| Underlying Price | % From Spot | P&L at Expiration |
|---|---|---|
| $0.01 | -99.9% | -$167.50 |
| $4.06 | -77.8% | -$167.50 |
| $8.12 | -55.7% | -$167.50 |
| $12.17 | -33.6% | -$167.50 |
| $16.23 | -11.5% | -$167.50 |
| $20.28 | +10.6% | +$60.48 |
| $24.33 | +32.7% | +$465.88 |
| $28.39 | +54.8% | +$871.28 |
| $32.44 | +76.9% | +$1,276.68 |
| $36.50 | +99.0% | +$1,682.07 |
When traders use long call on CGEM
Long calls on CGEM express a bullish thesis with defined risk; traders use them ahead of CGEM catalysts (earnings, product launches, macro events) when the expected upside justifies the premium and theta decay.
CGEM thesis for this long call
The market-implied 1-standard-deviation range for CGEM extends from approximately $12.16 on the downside to $24.52 on the upside. A CGEM long call expresses a directional view that the underlying closes above the strike plus premium at expiration, ideally with implied volatility holding or expanding to preserve extrinsic value through the hold period. Current CGEM IV rank near 19.40% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on CGEM at 117.60%. As a Healthcare name, CGEM options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to CGEM-specific events.
CGEM long call positions are structurally bullish; the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. CGEM positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move CGEM alongside the broader basket even when CGEM-specific fundamentals are unchanged. Long-premium structures like a long call on CGEM are particularly exposed to IV-crush risk through scheduled events (earnings, FDA decisions, central-bank meetings) where IV typically contracts post-event regardless of the directional outcome. Always rebuild the position from current CGEM chain quotes before placing a trade.
Frequently asked questions
- What is a long call on CGEM?
- A long call on CGEM is the long call strategy applied to CGEM (stock). The strategy is structurally bullish: A long call buys upside exposure with a fixed maximum loss equal to the premium paid; profit accrues if the underlying closes above the strike plus premium at expiration. With CGEM stock trading near $18.34, the strikes shown on this page are snapped to the nearest listed CGEM chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are CGEM long call max profit and max loss calculated?
- Max profit is unbounded; max loss equals the premium paid times 100. Breakeven is strike plus premium. For the CGEM long call priced from the end-of-day chain at a 30-day expiry (ATM IV 117.60%), the computed maximum profit is unbounded per contract and the computed maximum loss is -$167.50 per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a CGEM long call?
- The breakeven for the CGEM long call priced on this page is roughly $19.68 at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current CGEM market-implied 1-standard-deviation expected move is approximately 33.71%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a long call on CGEM?
- Long calls on CGEM express a bullish thesis with defined risk; traders use them ahead of CGEM catalysts (earnings, product launches, macro events) when the expected upside justifies the premium and theta decay.
- How does current CGEM implied volatility affect this long call?
- CGEM ATM IV is at 117.60% with IV rank near 19.40%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.